|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | Evolution of surgical skills training显示文摘外科的训练正在变化:100 年传统被法律、道德的担心为耐心的安全,工作小时限制,手术室时间的费用,和复杂并发症正在质问。训练的外科的模拟和技巧提供一个机会在在生活病人上尝试他们前在手术室环境外面教并且练习先进技巧。当使用真实仪器和录像设备操作在一个盒子训练员模仿了“织物”,模拟训练能向前是同样直的。更先进的、虚拟现实模拟器现在为普遍使用可得到、准备好了。早系统表明了他们的有效性和歧视的能力。更新的系统启用全面课程和完整的程序的模拟的开发。医药教育是的毕业生的认证委员会(ACGME ) 要求了训练和评估的新奇方法的发展。外科的组织正在打电话让方法保证技巧的维护,并且,进展 surgical 训练信任外科医生作为技术上能干。在他们的当前的形式的模拟器被表明了改进外科的居民的手术室表演。训练课程标准化的开发仍然是一个迫切、重要的议程,特别地为最小的侵略外科。一条创新、进步的途径,从航空的域借经验,能为外科的训练的下一个世纪提供基础,保证产品的质量。当技术发展,我们练习的方法将继续演变,到医生和病人的利益。 | Kurt E Roberts Robert L Bell Andrew J Duffy | 2006 | World Journal of Gastroenterology2006，12，20： | 8 |
| 3 | Controversies in the treatment of gastroesophageal reflux and achalasia显示文摘胃的食道的倒流疾病(GERD ) 和弛缓不能的有效治疗为这二作为标准答案建立了最小的侵略外科的 laparoscopic 外科的巨大的成功与更低的病态和死亡调节,更短的医院停留,更快的康复,和不太手术后的疼痛。在 GERD 的处理的一争吵作为比较喜欢的处理在 laparoscopic 反倒流外科(LARS ) 附近演变让 Barrett 的食管和过程的潜力减少食管的腺癌的风险。GERD 也与呼吸症状,气喘和喉的损害被联系了,并且第二争吵推动全部或部分的 fundoplication 是否是为 GERD 的更适当的处理的讨论。在 GERD 的处理的一种新、有希望的选择是 endoluminal 治疗。这种新处理选择的三种类型将被讨论:送到更低的食道的括约肌的射频精力,在胃的食道的连接的一个机械障碍的创造,并且更低的食道的括约肌的直接内视镜的紧缩。Laparoscopic 外科为弛缓不能为 GERD 而且同样永久的痊愈作为很有效的治疗被讨论不仅。这评论为弛缓不能分析三种很重要的处理选择:药,灵魂膨胀,和外科的治疗。因为他们的短半衰期和可变吸收,在弛缓不能的处理的药同样唯一的真非侵略的选择由于穷人不象 LARS 一样有效食道的倒空。第二种处理选择,灵魂膨胀,包含拉长更低的食管并且是仍然为弛缓不能考虑了最有效的非外科的处理。最后,为弛缓不能的外科的治疗和有关这个 laparoscopic 处理的二主要争吵被讨论。第一包含肌切开术被扩大到到胃上的程度,并且第二使反倒流过程的必要性和类型担心在肌切开术以后阻止 GERD。LARS 和 laparoscopic Heller 肌切开术是同意了在之上作为为 GERD 和弛缓不能的外科疗法的标准答案分别地。在一位富有经验的 laparoscopic 外科医生的手里,两个是为有有至少 90% 耐心的满足的优秀主观、客观的长期的结果的病人的安全、有效的治疗。 | Kurt E Roberts Andrew J Duffy Robert L Bell | 2006 | World Journal of Gastroenterology2006，12，20： | 4 |
| 4 | Heart Disease and Stroke Statistics—2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee显示文摘 | Donald Lloyd-Jones Robert Adams Mercedes Carnethon Giovanni De Simone T Bruce Ferguson Katherine Flegal Earl Ford Karen Furie Alan Go Kurt Greenlund Nancy Haase Susan Hailpern Michael Ho Virginia Howard Brett Kissela Steven Kittner Daniel Lackland Lynda L | 2009 | Circulation2009，，3： | 4 |
| 5 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases显示文摘The past decade has brought substantial advances in the management of inflammatory bowel diseases(IBD). The introduction of tumor necrosis factor(TNF) antagonists, evidence for the value of combination therapy, the recog-nition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The thera-peutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these ‘older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severityand response to therapy. | Jason Reinglas Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，32： | 3 |
| 6 | Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer显示文摘AIM:To analyze the impact of the GNAS1 T393C polymorphism on prognosis and histopathology of gastric cancer.METHODS:Genomic DNA was extracted from paraffinembedded tissues of 122 patients with primary gastric carcinoma and from the blood of 820 healthy white individuals.Allelic discrimination was performed by quantitative real-time polymerase chain reaction.Genotyping was correlated with histopathologic parameters and with overall survival according to the Kaplan-Meier approach and with multivariate analysis by multiple stepwise regression.RESULTS:Thirty-nine(32%) patients displayed a CC genotype,57(46.7%) a CT genotype and 26(21.3%) a TT genotype.The frequency of the C allele(fC) in the patient group was 0.55,which was not signif icantly different from that of healthy blood donors.The distribution was compatible with the Hardy-Weinberg equilibrium.Analysis of clinicopathological parameters did not show any signif icant correlation of the T393C genotype with gender(P=0.50),differentiation(P=0.29),pT-category(P=0.19),pN-category(P=0.30),pM-category(P=0.25),R-category(P=0.95),the classifications according to WHO(P=0.34),Laurén(P=0.16),Goseki(P=1.00) and Ming(P=0.74).Dichotomization between C+(CC+CT) and C-genotypes(TT),however,revealed signif icantly more advanced tumor stages(P=0.023) and lower survival rates(P=0.043) for C allele carriers.CONCLUSION:The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers. | Hakan Alakus Stefan P Mnig Ute Warnecke-Eberz Gül Alakus Günther Winde Uta Drebber Klaus J Schmitz Kurt W Schmid Kathrin Riemann Winfried Siffert Elfriede Bollschweiler Arnulf H Hlscher Ralf Metzger | 2009 | World Journal of Gastroenterology2009，15，48： | 3 |
| 7 | Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?显示文摘Inflammatory bowel disease(IBD) is a lifelong, progres-sive disease that has disabling impacts on patient's lives. Given the complex nature of the diagnosis of IBD and its management there is consequently a large economic burden seen across all health care systems. Quality in-dicators(QI) have been created to assess the different fa?ades of disease management including structure, process and outcome components. Their development serves to provide a means to target and measure quality of care(Qo C). Multiple different QI sets have been published in IBD, but all serve the same purpose of trying to achieve a standard of care that can be attained on a national and international level, since there is still a major variation in clinical practice. There have been many recent innovative developments that aim to improve Qo C in IBD including telemedicine, home biomarker assessment and rapid access clinics. These are some of the novel advancements that have been shown to have great potential at improving Qo C, while offloading some of the burden that IBD can have vis-a-vis emergency room visits and hospital admissions. The aim of the current review is to summarize and discuss available QI sets and recent developments in IBD care including telemedicine, and to give insight into how the utilization of these tools could benefit the Qo C of IBD patients. Additionally, a treating-to-target structure as well as evidence surrounding aggressive management directed at tighter disease control will be presented. | Matthew Strohl Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，22： | 2 |
| 8 | Temperature Effects On Subsurface Equipment In Steam Injection Systems显示文摘 | Kurt Leutwyler Bigelow H L | 1965 | Journal of Petroleum Technology1965，36，14： | 1 |
| 9 | Estimation of an earthquake focal mechanism from a satellite radar interferogram: Application to the December 4,1992 Landers aftershock显示文摘 | Arnaud Sergent Dominique Jacq | 1995 | Geophysical Research Letters1995，22，9： | 1 |
| 10 | Neurotrophin secretion: current facts and future prospects 显示文摘 | VOLKMAR L KURT G MARZIA M | 2003 | Progress in Neurobiology2003，69，： | 1 |
| 11 | Investigation into the importance of the stomatal pathway in the exchange of PCBs between air and plants 显示文摘 | Barber J L Kurt P B Thomas G 0 | 2002 | Environmental Science and Technology2002，36，： | 1 |
| 12 | Depressive and Anxiety Disorders in Patients Presenting With Physical Complaints显示文摘 | Kurt Kroenke Jeffrey L Jackson Judith Chamberlin | 1997 | The American Journal of Medicine1997，，5： | 1 |
| 13 | Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding显示文摘 | Joseph L Kim Kurt A Morgenstern James P Griffith Maureen D Dwyer John A Thomson Mark A Murcko Chao Lin Paul R Caron | 1998 | Structure1998，，1： | 1 |
| 14 | Hepatitis C virus treatment in the real world: optimising treatment and access to therapies显示文摘 | Zoulim Fabien Liang T Jake Gerbes Alexander L Aghemo Alessio Deuffic-Burban Sylvie Dusheiko Geoffrey Fried Michael W Pol Stanislas Rockstroh Ju?rgen Kurt Terrault Norah A Wiktor Stefan | 2015 | Gut2015，，11： | 1 |
| 15 | Gene therapy: adenovirus-mediated hum an bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor c ell proliferation and differentiation in vitro and bone formation in vivo显示文摘 | Fang X Kurt M | 1999 | J Orthop Res1999，17，1： | 1 |
| 16 | Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus 显示文摘 | Kurt -Jones EA Popova L Kwinn L | 2000 | Nat Immunol2000，1，5： | 1 |
| 17 | Interstitial iodine 125 in ad-vanced recurrent squamous cell carcinoma of the head and neckwith follow-up evaluation of carotid artery by ultrasound显示文摘 | Kurt Y Rose M Craig L | 1996 | Ann Orol Rhinol Laryngol1996，105，12： | 1 |
| 18 | CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease – IVUS substudy of the ENCORE trials显示文摘 | Matthias Hermann Dieter Fischer Michael M. Hoffmann Theo Gasser Kurt Quitzau Thomas Meinertz Thomas Münzel Thomas F. Lüscher | 2011 | Atherosclerosis2011，，1： | 1 |
| 19 | Luminescence from minerals excited by subnanosecond pulses of runaway electrons generated in an atmospheric-pressure high-voltage discharge in air显示文摘 | Babich L P Becker Kurt H Loiko T V | 2009 | IEEE Transactions on Plasma Science2009，37，11： | 1 |
| 20 | Synthesis of azolyl carboximidamides as ligands for Zn(11)and Cu(11):application of the Zn(11)complexes as catalysts for the copolymerization of carbon dioxide and epoxides显示文摘 | Martin W Kurt W Marion L | 2006 | J Org Chem2006，71，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员